What is exon skipping and how does it work?
In order to explain the concept of exon skipping, it is first necessary to explain how genes work and how mutations in the dystrophin gene can cause both Duchenne and Becker muscular dystrophy.
- What are genes?
- What are exons?
- What happens in Becker muscular dystrophy?
- What impact does a Becker mutation have on the dystrophin protein?
- What happens in Duchenne muscular dystrophy?
- How can exon skipping help?
- Does this really work?
- Is there a clinical trial?
- Will it work for everyone with Duchenne muscular dystrophy?
- Will the same 'molecular patch' work for everyone?
- Are ‘molecular patches' a cure?
- Further information and links
DNA is an extremely long molecule which contains the instructions to create and maintain our bodies. A gene is a section of DNA that contains the instructions for the production of one specific protein. Proteins are essential parts of cells and play a role in every process occurring within the cell, as well as having structural or mechanical functions which help maintain the cells' shape. It is estimated that we have about 30,000 different genes.
Genes are divided into sections called exons and introns. Exons are the sections of DNA that code for the protein and they are interspersed with introns which are also sometimes called 'junk DNA'. The introns are cut out and discarded in the process of protein production, to leave just the exons. The dystrophin gene is our largest gene- it has 79 exons which are joined together like the pieces of a puzzle.
Let's zoom in on exons 68 to 75 to look at this a bit more closely:
In Becker muscular dystrophy an exon is deleted, for example exon number 74 in the diagram:
Although a part of the gene is missing, exon 73 can join up with exon 75, and the puzzle can be completed to the end of the gene:
The dystrophin protein normally sits in the membrane that surrounds muscle fibres like a skin, and protects the membrane from damage during muscle contraction. Without dystrophin the muscle fibre membranes become damaged and eventually the muscle fibres die.
Dystrophin is a very large protein with a section in the middle consisting of lots of repeated segments (in green below) and it is known that the protein can still work to some extent if some of these repeated segments are missing. Individuals with Becker muscular dystrophy have some of these repeated segments missing and have relatively mild symptoms- often being able to still walk into their 40s and 50s.
A man has even been known to be still walking at 61 years of age, despite having a deletion of 46% of the dystrophin gene!
In Duchenne muscular dystrophy an exon, or exons are deleted which interfere with the rest of the gene being pieced together. In our example (using exons 50-57), exon 52 illustrates this:
Exon 51 can not join up with exon 53, which prevents the rest of the exons being assembled. For the dystrophin protein to work it must have both ends of the protein. Therefore, this mutation results in a completely non-functional dystrophin protein and the severe symptoms of Duchenne muscular dystrophy.
As the name suggests, the principle of exon skipping is to encourage the cellular machinery to 'skip over' an exon. Small pieces of DNA called antisense oligonucleotides (AOs) or 'molecular patches' are used to mask the exon that you want to skip, so that it is ignored during protein production. In our example, if we use a 'molecular patch' designed to mask exon 53:
Exon 51 can now join up to exon 54 and continue to make the rest of the protein, with exons 52 and 53 missing in the middle:
Therefore, exon skipping may be able to reduce the symptoms of Duchenne muscular dystrophy, to those more like Becker muscular dystrophy.
So far scientists have shown this technique to be effective in a mouse model of Duchenne muscular dystrophy (the mdx mouse) and in human Duchenne muscular dystrophy muscle cells grown in the laboratory.
Several clinical trials have now been conducted that show that injecting a molecular patch into the blood stream or under the skin results in the production of dystrophin in the muscles. No serious side-effects were observed. There are three companies involved in conducting clinical trials of exon skipping. The principal of exon skipping is the same for all of the clinical trials but the molecular patch being tested has a slightly different chemical formulation.
- The Dutch company Prosensa has formed a partnership with GSK to test a molecular patch to skip exon 51 and you can read about the latest results of their trial here.
- AVI Biopharma conducted a clinical trial in the UK of a exon 51 molecular patch developed by the MDEX consortium with funding from the Muscular Dystrophy Campaign. Read about the results of this trial here.
The next step is to find out if the increase in dystrophin in the muscles results in improved muscle function or at least slows the deterioration of the muscle. Clinical trials have been started to determine this and continue to monitor the safety of exon skipping.
AVI Biopharma now plans to test higher doses of the molecular patch to try to gain a consistently strong response to the molecular patch. They are planning to conduct this trial in the US. Read about it here.
There are several other exon skipping trials ongoing (click on the link to read the clinical trial summary):
- Testing two different dosing regimes of the exon 51 molecular patch (Prosensa/GSK)
- Investigating exon 51 skipping in boys who are no longer able to walk (Prosensa/GSK)
- Investigating the skipping of exon 44 (Prosensa)
The challenge with all of these trials is to produce enough dystrophin in as many muscles as possible (including the heart) to prolong and improve the quality of life for boys with Duchenne muscular dystrophy.
Visit our clinical trials section for more information
It is thought that skipping one or two exons would be able to treat around 83% of the genetic errors causing Duchenne muscular dystrophy.
No, the dystrophin gene is very large and the genetic errors associated with Duchenne muscular dystrophy occur in different places along this gene. There are however some common areas for mutations and initially 'molecular patches' will be made for these. The clinical trials are starting with exon 51 which would be applicable for around 13% of boys. Once the technology has been shown to be effective for a particular error it will be possible to design other 'patches'. A clinical trial has been started for a exon 44 molecular patch which is applicable to about 6 percent of boys. The companies have said that they have started preclinical research on patches for exon 50, 45, 52, 53 and 55.
Scientists hope that this type of therapy will halt or even reverse the symptoms of Duchenne muscular dystrophy so that the symptoms are more like those of boys with Becker muscular dystrophy. It will not be a cure because if proven to be effective, this treatment would need to be repeated regularly- how often will become apparent during clinical trials.
Read about the exon skipping research we fund.
Current clinical trials for Duchenne muscular dystrophy.
Visit AVI Biopharma's website.
Visit Prosensa's website.
If you have any questions, please contact us on 020 7803 4800 or firstname.lastname@example.org
It is only through your contributions that we can continue to fund the vital work that takes us closer to finding treatments and cures for muscle disease. Donate now and help change the lives of thousands of people living with muscle disease.